Post Resch Tallon Group Inc. Trims Position in Exelixis, Inc. $EXEL

Post Resch Tallon Group Inc. reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 83.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 8,428 shares of the biotechnology company’s stock after selling 41,969 shares during the period. Post Resch Tallon Group Inc.’s holdings in Exelixis were worth $492,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of EXEL. BlackRock Inc. acquired a new position in shares of Exelixis during the second quarter worth $1,581,991,000. Dimensional Fund Advisors LP lifted its holdings in Exelixis by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company’s stock worth $184,391,000 after buying an additional 39,920 shares during the period. Assetmark Inc. grew its position in shares of Exelixis by 1.7% in the 1st quarter. Assetmark Inc. now owns 3,388,920 shares of the biotechnology company’s stock valued at $145,351,000 after buying an additional 58,149 shares during the last quarter. First Trust Advisors LP increased its stake in shares of Exelixis by 62.0% in the first quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company’s stock valued at $108,726,000 after buying an additional 970,144 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Exelixis by 30.7% in the second quarter. Bank of America Corp DE now owns 2,149,397 shares of the biotechnology company’s stock valued at $116,949,000 after buying an additional 504,660 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other Exelixis news, Director Mary Beckerle sold 9,812 shares of Exelixis stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the sale, the director directly owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. UBS Group set a $55.00 price objective on Exelixis in a research note on Monday, August 3rd. Citizens Jmp raised their price target on shares of Exelixis from $50.00 to $55.00 and gave the stock a “market outperform” rating in a report on Wednesday, June 24th. Citigroup restated a “market outperform” rating on shares of Exelixis in a research report on Monday, September 14th. Morgan Stanley upped their price objective on shares of Exelixis from $50.00 to $53.00 and gave the company an “equal weight” rating in a research note on Thursday, July 23rd. Finally, William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.36.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks slightly raises long-term earnings forecast: Zacks Research increased its FY2028 EPS estimate for Exelixis to $4.22 from $4.21. Although the adjustment is modest and the firm maintains a “Hold” rating, the revision indicates stable expectations for future profitability. Zacks Research earnings estimate update
• Positive Sentiment: Some valuation commentary remains favorable: Coverage highlighted Exelixis as a potential value stock, while another analysis suggested the shares may be undervalued as investors focus on earnings and the company’s continued growth. Exelixis’ latest quarterly results showed earnings above expectations and revenue growth of 10.6% year over year. Zacks value stock analysis Exelixis may be undervalued analysis
• Neutral Sentiment: Truist raises its target but remains cautious: Truist Financial lifted its price target from $52 to $54 while retaining a “Hold” rating. The increase is supportive, but the new target still implies approximately 8.5% downside from the referenced share price. Truist raises Exelixis price target
• Negative Sentiment: RBC cuts its price target: Royal Bank of Canada reduced its target to $45 from $46 and kept a “Sector Perform” rating. The target implies roughly 23.8% downside, reinforcing concerns that the shares may be fully valued at current levels. RBC cuts Exelixis price target
• Negative Sentiment: Cabozantinib patent timing remains an overhang: Investors are assessing whether Exelixis’ valuation fully reflects the remaining patent protection for its key cancer drug, cabozantinib. Potential future patent-related erosion could limit upside and is contributing to caution around the stock. Exelixis cabozantinib patent analysis

Exelixis Stock Performance

Shares of EXEL stock opened at $59.02 on Friday. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $61.14. The stock has a 50 day simple moving average of $56.13 and a two-hundred day simple moving average of $52.15. The company has a market cap of $14.62 billion, a P/E ratio of 18.56, a PEG ratio of 1.74 and a beta of 0.47.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.85 by $0.06. The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The company’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS. On average, research analysts predict that Exelixis, Inc. will post 3.19 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.